NuVasive, Inc.
https://www.nuvasive.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NuVasive, Inc.
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Globus Medical To Merge With NuVasive In $3.1Bn All-Stock Deal Analysts Foresee Challenges
Analysts from Piper Sandler and BTIG noted that the proposed merger between Globus Medical and NuVasive raises concerns about cultural fit, approach to commercialization and profitability, as well as anti-trust issues.
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
FDA’s QMSR: 3 Experts Read Draft Rule Comments So You Don’t Have To. Here’s What They Saw
Longtime industry experts Kim Trautman, Steve Niedelman and Dennis Gucciardo spoke with Medtech Insight about interesting or insightful stakeholder comments on the US FDA’s proposed Quality Management System Regulation. Part one of two.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Implantable Devices
- Monitoring Equipment & Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Biotronic NeuroNetwork
- BNN Holdings Corp
- Ellipse Technologies, Inc.
- Impulse Monitoring, Inc.
- Mega Surgical
- NuVasive®, Inc
- NuVasive Clinical Services
- NuVasive Specialized Orthopedics, Inc.
- Simplify Medical, Inc.
- Vertera Spine
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice